- Home
- CPS vs XNCR Comparison
CPS vs XNCR Comparison
Compare CPS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPS
- XNCR
- Stock Information
- Founded
- CPS 1960
- XNCR 1997
- Country
- CPS United States
- XNCR United States
- Employees
- CPS N/A
- XNCR N/A
- Industry
- CPS Auto Parts:O.E.M.
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- CPS Consumer Discretionary
- XNCR Health Care
- Exchange
- CPS Nasdaq
- XNCR Nasdaq
- Market Cap
- CPS 462.2M
- XNCR 547.8M
- IPO Year
- CPS N/A
- XNCR 2013
- Fundamental
- Price
- CPS $39.04
- XNCR $8.49
- Analyst Decision
- CPS Hold
- XNCR Buy
- Analyst Count
- CPS 1
- XNCR 10
- Target Price
- CPS $12.00
- XNCR $23.33
- AVG Volume (30 Days)
- CPS 227.6K
- XNCR 718.3K
- Earning Date
- CPS 10-30-2025
- XNCR 11-05-2025
- Dividend Yield
- CPS N/A
- XNCR N/A
- EPS Growth
- CPS N/A
- XNCR N/A
- EPS
- CPS 1.65
- XNCR N/A
- Revenue
- CPS $2,719,148,000.00
- XNCR $146,929,000.00
- Revenue This Year
- CPS $2.46
- XNCR $22.06
- Revenue Next Year
- CPS $3.29
- XNCR N/A
- P/E Ratio
- CPS $23.46
- XNCR N/A
- Revenue Growth
- CPS N/A
- XNCR N/A
- 52 Week Low
- CPS $10.38
- XNCR $6.92
- 52 Week High
- CPS $39.79
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- CPS 74.19
- XNCR 55.28
- Support Level
- CPS $37.24
- XNCR $8.26
- Resistance Level
- CPS $39.67
- XNCR $8.73
- Average True Range (ATR)
- CPS 1.54
- XNCR 0.38
- MACD
- CPS -0.17
- XNCR 0.06
- Stochastic Oscillator
- CPS 87.02
- XNCR 69.03
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.